Results 1 to 10 of about 65,815 (207)

Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid [PDF]

Frontiers in Immunology, 2019
Bullous pemphigoid (BP) is an organ-specific autoantibody-mediated blistering skin disease that mainly affects the elderly. Typical clinical features include the widespread blisters, often preceded by and/or associated with itchy urticarial or eczema ...
Kaisa Tasanen, Outi Varpuluoma, Wataru Nishie   +2 more
doaj   +4 more sources

Dipeptidyl Peptidase-4 Inhibitors Associated with Lower Psoriatic Disease Risk in Type 2 Diabetes: A 13-Year Nationwide Cohort Study with Mechanistic Validation [PDF]

Acta Dermato-Venereologica
Psoriatic disease, encompassing psoriasis and -psoriatic arthritis, is a chronic inflammatory condition with bidirectional associations with type 2 diabetes mellitus.
Chih-Tsung Hung, Chi-Hsiang Chung, Tsu-Hsuan Weng, Chun-Teng Tsai, Wu-Chien Chien, Yung-Lung Chang   +5 more
doaj   +2 more sources

Nonglycemic effects of dipeptidyl peptidase-4 inhibitors

Терапевтический архив, 2013
The review considers the major nonglycemic effects of dipeptidyl peptidase-4 inhibitors commonly used in diabetological practice, by using as an example sitagliptin, the first and most investigated representative of this class.
A S Ametov, L L Kamynina
doaj   +2 more sources

Comparative effectiveness of dipeptidyl peptidase-4 (DPP-4) inhibitors and human glucagon-like peptide-1 (GLP-1) analogue as add-on therapies to sulphonylurea among diabetes patients in the Asia-Pacific region: a systematic review [PDF]

, 2014
The prevalence of diabetes mellitus is rising globally, and it induces a substantial public health burden to the healthcare systems. Its optimal control is one of the most significant challenges faced by physicians and policy-makers.
A Juutilainen, AA Riedel, AI Adler, AJ Garber, AR Saltiel, BD Green, BI Yan, BM Scirica, Brian C. Y. Fong, C Castell, C Levetan, Carmen K. M. Fan, CC Cowie, CE Van Dijk, CJ Bailey, CN Chan, Daisy D. X. Zhang, DC Simonson, DR Owens, DS Schade, FA Guisasola, François Blachier, Harry H. X. Wang, J Lopatynski, J Mest H, J Rosenstock, K Kaku, Kirin Q. L. Liu, L Groop, M Kobayashi, M Stumvoll, M Takihata, Mandy W. M. Kwan, Martin C. S. Wong, MC Wong, N Inagaki, N Inagaki, O Mosenzon, R Kawamori, RA DeFronzo, S Aronoff, S Clement, SE Kahn, SE Kahn, SE Nissen, Shannon T. S. Li, Sian M. Griffiths, Sky W. M. Chan, SL Zhang, T Kadowaki, V Mohan, W Gareth, W Yang, WB White, Y Guan, Y Seino, Y Seino, YG Kim, Z Zeng   +58 more
core   +13 more sources

SAFETY PROFILE OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS [PDF]

Trakia Journal of Sciences, 2023
Dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors) are oral antidiabetic agents commonly used for the treatment of type 2 diabetes mellitus. More than ten years of clinical experience with this group of drugs provides evidence of their efficacy and ...
M. Ganeva
doaj   +1 more source

Trelagliptin (SYR-472, Zafatek), Novel Once-Weekly Treatment for Type 2 Diabetes, Inhibits Dipeptidyl Peptidase-4 (DPP-4) via a Non-Covalent Mechanism. [PDF]

PLoS ONE, 2016
Trelagliptin (SYR-472), a novel dipeptidyl peptidase-4 inhibitor, shows sustained efficacy by once-weekly dosing in type 2 diabetes patients. In this study, we characterized in vitro properties of trelagliptin, which exhibited approximately 4- and 12 ...
Charles E Grimshaw, Andy Jennings, Ruhi Kamran, Hikaru Ueno, Nobuhiro Nishigaki, Takuo Kosaka, Akiyoshi Tani, Hiroki Sano, Yoshinobu Kinugawa, Emiko Koumura, Lihong Shi, Koji Takeuchi   +11 more
doaj   +1 more source

Predictive Clinical Parameters and Glycemic Efficacy of Vildagliptin Treatment in Korean Subjects with Type 2 Diabetes [PDF]

Diabetes & Metabolism Journal, 2013
BackgroundThe aims of this study are to investigate the glycemic efficacy and predictive parameters of vildagliptin therapy in Korean subjects with type 2 diabetes.MethodsIn this retrospective study, we retrieved data for subjects who were on twice-daily
Jin-Sun Chang, Juyoung Shin, Hun-Sung Kim, Kyung-Hee Kim, Jeong-Ah Shin, Kun-Ho Yoon, Bong-Yun Cha, Ho-Young Son, Jae-Hyoung Cho   +8 more
doaj   +1 more source

Dynamics of total volume of pancreatic α‐ and β ‐cells under the influence sulfonylureas and their combination with dipeptidyl peptidase‐4 inhibitors

Endocrinology, Diabetes & Metabolism, 2021
Objective Sulfonylureas and dipeptidyl peptidase‐4 inhibitors have a multidirectional effect on pancreatic cells. We aimed to evaluate the effects of these drugs on β‐ and α‐cells in rats aged 12 months with type 2 diabetes mellitus when administered in ...
Tuchina Taisiia Pavlovna, Skotnikova Kseniia Petrovna, Vtorushina Anna Anatolievna, Uskov Ivan Sergeyevich, Rogoza Olga Vladimirovna, Grozov Roman Viktorovich, Babenko Alina Yurievna, Galagudza Mikhail Mikhailovich   +7 more
doaj   +1 more source

The effect of sitagliptin on hepatic ischemic reperfusion injury in rats

Medical Journal of Dr. D.Y. Patil Vidyapeeth, 2020
Background: Dipeptidyl peptidase-4 (DPP4, DPPIV, CD26, EC 3.4.14.5) was found out more than four decades ago as a serine protease that severs N-terminal dipeptides from peptide substrates. DPP-4 inhibitors have been used in many animal models of lung and
Song-Chol Mun, Hye-Sun Hong
doaj   +1 more source

Impact of sitagliptin on endometrial mesenchymal stem-like progenitor cells : a randomised, double-blind placebo-controlled feasibility trial [PDF]

, 2020
Background: Recurrent pregnancy loss (RPL) is associated with the loss of endometrial mesenchymal stem-like progenitor cells (eMSC). DPP4 inhibitors may increase homing and engraftment of bone marrow-derived cells to sites of tissue injury.
Brighton, Paul (Paul J.), Brosens, Jan J., Da Costa, Maria José Minhoto Diniz, Ewington, Lauren J., Fishwick, Katherine, Fujihara, Risa, Kimani, Peter K., Lacey, Lauren, Lucas, Emma S., Muter, Joanne, Polanco, Angela, Quenby, Siobhan, Takeda, Satoru, Tewary, Shreeya   +13 more
core   +1 more source